Skip to main content

Advertisement

ADVERTISEMENT

News

Efficacy of Autologous MSCs for Lower Limb Ulcers

https://clinicaltrials.gov/study/NCT06326203

A 40-patient Phase II RCT will evaluate the safety and efficacy of autologous MSC therapy for lower limb ulcers in patients w/ critical limb ischemia. The primary outcome is amputation at 120 days and ulcer healing up to 120 days. Estimated study completion is Dec 2027. clinicaltrials.gov

Advertisement

Advertisement

Advertisement